Company intelligence / Profile preview
Alfresa
- Ownership
- Public · 2784
- Employees
- ~12500
- Development stage
- Commercial
Overview
Alfresa is one of Japan’s largest healthcare groups specializing in the wholesale distribution of pharmaceuticals and medical devices. It also manufactures select proprietary drugs for neuropsychiatric and rare diseases. The group has commercialized several products including Modiodal for sleep disorders and Sabril for epilepsy. Its diagnostics division develops innovative tests such as fecal occult blood kits for cancer screening.
- Therapeutic areas
- GastroenterologyImmunologyNeurology
- Modalities
- Small moleculeDiagnostic reagentMedical device
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $2.6B
- Total revenue
- $19.6B
- Enterprise value
- $1.5B
Beyond the preview
Go deeper on Alfresa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfresa.